Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-Exacerbated Respiratory Disease: A Prospective Trial.
CONCLUSIONS: High-dose aspirin therapy for 8 weeks paradoxically increases markers of type 2 inflammation in subjects with aspirin-exacerbated respiratory disease, despite reducing nasal symptoms. This effect of aspirin is unique to aspirin-exacerbated respiratory disease and not observed in aspirin-tolerant asthmatics. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01597375.
PMID: 30978291 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Cahill KN, Cui J, Kothari P, Murphy K, Raby BA, Singer J, Israel E, Boyce JA, Laidlaw TM Tags: Am J Respir Crit Care Med Source Type: research
More News: Aspirin | Asthma | Clinical Trials | Israel Health | Middle East Health | Respiratory Medicine